COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Hormone Analogue

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01632592
Recruitment Status : Withdrawn (No funding available)
First Posted : July 3, 2012
Last Update Posted : January 24, 2014
Information provided by (Responsible Party):
Steven K. Grinspoon, MD, Massachusetts General Hospital

Brief Summary:

Obesity is strongly associated with risk of cardiovascular disease (CVD). Data increasingly suggest that visceral adipose tissue (VAT) accumulation -- or increased abdominal fat -- is particularly deleterious to cardiovascular health, but further study is needed to test this idea. Increased abdominal fat may also be associated with lower secretion of a hormone called growth hormone (GH), which helps the body burn fat. The current study aims to carefully characterize relationships between abdominal fat and CVD. In addition, by using a medication called growth hormone releasing hormone, which is a strategy to reduce abdominal fat, the investigators will test the hypothesis that abdominal fat contributes uniquely to increased arterial inflammation.

In the first part of this study, the investigators will investigate both lean (healthy weight) individuals and individuals with increased abdominal fat. The investigators will study their body composition, cardiovascular risk measures, insulin sensitivity, and growth hormone dynamics, with the hypothesis that abdominal fat, independent of general obesity, will be strongly associated with arterial wall thickening and atherosclerotic inflammation. The investigators will assess arterial wall thickness, plaque morphology, and atherosclerotic inflammation, and the investigators will determine associations between these variables and regional fat accumulation, with particular attention to abdominal fat.

The second, treatment part of the study will be only for individuals with increased abdominal fat who are found to have low growth hormone secretion. In that part of the study, the investigators will test the effects of a growth hormone releasing hormone (GHRH) analogue to reduce abdominal fat and, consequently, reduce arterial inflammation. The investigators hypothesize that abdominal fat reduction, independent of changes in growth hormone, will reduce arterial inflammation and arterial wall thickness.

Condition or disease Intervention/treatment Phase
Abdominal Obesity Drug: Tesamorelin Drug: Placebo Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Abdominal Obesity, Cardiovascular Inflammation, and Effects of a Growth Hormone Releasing Hormone Analogue to Reduce Inflammation
Study Start Date : January 2014
Actual Primary Completion Date : January 2014
Actual Study Completion Date : January 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hormones

Arm Intervention/treatment
Experimental: Growth Hormone Releasing Hormone
Growth Hormone Releasing Hormone analogue, 2mg subcutaneously every day for 12 months.
Drug: Tesamorelin
The Growth Hormone Releasing Hormone analogue tesamorelin, 2mg subcutaneously daily by injection

Placebo Comparator: Placebo Drug: Placebo
placebo given by injection 2mg subcutaneously daily

Primary Outcome Measures :
  1. aortic "target to background ratio" (Aortic TBR) [ Time Frame: 12 months ]
    aortic target-to-background ratio is a measure of the inflammation in the wall of the aorta that is made by positron emission tomography (PET) scanning in conjunction with computed tomography (CT) scanning.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion/Exclusion Criteria:

Inclusion Criteria for Lean Controls:

  1. Men and women age 18-55y
  2. BMI > 18.5 and < 25 kg/m2
  3. Waist circumference < 102 cm in men and <88cm in women

Inclusion criteria for Abdominal Obesity:

  1. Men and women age 18-55y
  2. BMI ≥ 30kg/m2
  3. Abdominal obesity as defined by waist circumference ≥ 102 cm in men and ≥ 88 cm in women
  4. Relative GH deficiency as demonstrated by peak GH to arginine/GHRH stimulation test of < 9mcg/L (for treatment portion only)
  5. Negative age-appropriate screening for cancer performed by primary care physician (e.g., negative mammogram if F > 50yo) (For treatment portion only)

Exclusion criteria for all subjects:

  1. Obesity due to known secondary causes
  2. Use of weight-lowering drugs or previous weight loss surgery
  3. Use of gonadal steroids, GH, GHRH, glucocorticoids, megesterol acetate, antidiabetic agents, or any other hormonal medication judged by the investigator to be inappropriate within the past 6 months. Use of physiologic testosterone replacement will be allowed.
  4. Statin use
  5. Known coronary artery disease or peripheral vascular disease, or any history of stroke or significant chest pain
  6. Known auto-immune or inflammatory disease
  7. Any surgery or significant injury (including fracture or other trauma) within the past 6 months
  8. Hemoglobin < 11g/dL, fasting glucose > 126mg/dL, creatinine <1.5mg/dL, or AST > 2.5x upper limit of normal
  9. FSH > 20 IU/L (women only)
  10. Positive urine pregnancy test, actively seeking pregnancy, or breastfeeding
  11. Prior history of pituitary disease, pituitary surgery, or head irradiation, or any other condition known to affect pituitary function
  12. Infectious illness in the past 3 months, or chronic infectious illness
  13. Allergy to iodine containing contrast media
  14. Active illicit drug use
  15. For women of childbearing potential, failure to use an acceptable form of non-hormonal birth control
  16. Active malignancy: For the treatment part of the study, all active malignancy will be excluded. For the observational part of the study (which involves no intervention) basal cell carcinoma and low grade cervical or anal intraepithelial neoplasms will be allowed.
  17. History of colon cancer (treatment part only)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01632592

Layout table for location information
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Massachusetts General Hospital
Layout table for investigator information
Principal Investigator: Steven Grinspoon, MD Massachusetts General Hospital
Layout table for additonal information
Responsible Party: Steven K. Grinspoon, MD, Professor of Medicine, Harvard Medical School, Massachusetts General Hospital Identifier: NCT01632592    
Other Study ID Numbers: 2012p-000917
First Posted: July 3, 2012    Key Record Dates
Last Update Posted: January 24, 2014
Last Verified: January 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Obesity, Abdominal
Nutrition Disorders
Body Weight
Signs and Symptoms
Pathologic Processes
Growth Substances
Physiological Effects of Drugs